

BIBLIOGRAPHY

- Adedoyin A., Prakash C., O'Shea D., Blair IA. and Wilkinson GR.1994. Stereo selective disposition of hexobarbital and its metabolites: Relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. *Pharmacogenetics* 4: 27-38.
- Adedoyin A., Arns PA., Richard WO., Wilkinson GR.and Branch RA.1998 Selective Effect of liver disease on the activity of specific metabolising enzymes:investigation of cytochrome P450 2C19 and 2D6. *Clin Pharmacol Ther* 64:8-17.
- Andersson T., Regardh C-G., Lou Y-C., Zhang Y., Dahl ML. and Bertilsson L.1992. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. *Pharmacogenetics* 2: 25-31.
- Andersson T., Miners JQ. And Veronese ME. 1993. Identification of human liver Cytochrome P450 isoforms mediating omeprazole metabolism. *Br J Clin Pharmacol* 36:521-30.
- Aynacioglu AS., Sachse C., Bozkurt A., Kortunay S., Nacak M., Schroder T., Kayaalp SO.,Roots I. and Brockmoller J. 1999. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. *Clin Pharmacol Ther* 66(2): 185-92.
- Badyal D.K.and Dadhich A.P. 2001. Cytochrome P450 and drug interactions. *Indian Journal of Pharmacology* 33: 248-259.
- Balian JD., Sukhova N., Harris JW., Hewett J., Pickel L., Goldstein JA., Woosley RL. and Flockhart DA.1995. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. *Clin Pharmacol Ther* 57: 662-669.

- Barnes HJ., Arlotto MP. and Waterman MR. 1991. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in *Escherichia coli* *PNAS (USA)* 88:5597-5601.
- Bathum L., Skjelbo E., Mutabingwa TK., Madsen H., Horder M. and Brosen K. 1999. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. *Br J Clin Pharmacol* 48:395-401.
- Baumann P., Jonzier-Perez M., Kerb L., K pfer A., Tinguely D. and Sch pff J. 1986. Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. *Int Clin Psychopharmacol* 1: 102-112.
- Benhamou S., Bouchardy C. and Dayer P. 1997. Lung cancer risk in relation to mephenytoin hydroxylation activity. *Pharmacogenetics* 7: 157-159.
- Bertilsson L., Henthorn TK., Sanz E., Tybring G., S awe J and Vill en T. 1989. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. *Clin Pharmacol Ther* 45:348-355.
- Blaisdell J., Mohrenweiser H., Jackson J., Ferguson S., Coulter S., Chanas B., Xi T., Ghanayem B. and Goldstein JA. Identification and functional characterization of new potentially defective alleles of human CYP2C19. *Pharmacogenetics* 12: 703-11.
- Bonay AM, Jonville-Bera AP., Diot P., Lemarie E., Levandier M. and Autret E. 1993. Possible interaction between phenobarbitone, carbamazepine and itraconazole. *Drug Safety* 9: 309-11.

- Brøsen K., deMoraes SMF., Meyer UA. and Goldstein JA. 1995. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. *Pharmacogenetics* 5: 312-317.
- Buck M.L. 1997. The cytochrome P450 enzyme system and its effect on drug metabolism. *Pediatric Pharmacotherapy* 3(5): 94.
- Chang M., Dahl ML., Tybring G., Gotharson E. and Bertilsson L. 1995. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. *Pharmacogenetics*. 5:358-63.
- Chiba K. 1998. Genetic polymorphism of the CYP2C subfamily. *Nippon Yakurigaku Zasshi* 112:15-21
- Coller JK., Somogyi AA. and Bochner F. 1997. Association between CYP2C19 genotype and proguanil oxidative polymorphism. *Br J Clin Pharmacol* 43:659-60.
- Collman J. P., Brauman J. I., Meunier B., Hayashi T., Kodadek, T., and Raybuck, S. A. 1985. Epoxidation of olefins by cytochrome P-450 model compounds: kinetics and stereochemistry of oxygen atom transfer and origin of shape selectivity. *J. Am. Chem. Soc.* 107, 2000-2005.
- Correia M.A. 1998. Drug Bio-transformation. *In Basic and Clinical Pharmacology*. Katzung, B.G., ed 7th pp 50-51. New Jersey : Prentice-Hall International Inc.
- Crovo PB., Trapnell CB. and Rocco LE. 1999. The effect of rifampicin and rifabutin on the Pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin Pharmacol Ther* 65: 428-38.

- Daly AK., Brockmöller J., Broly F., Eichelbaum M., Evans WE., Gonzalez FJ., Huang J-D., Idle JR., Ingelman-Sundberg M., Ishizaki T., Jacqz-Aigrain E., Meyer UA., Nebert DW., Steen VM., Wolf CR. and Zanger UM. 1996. Nomenclature for human *CYP2D6* alleles. *Pharmacogenetics* 6: 193-201.
- Degtyarenko K.N. 1995. Structural domains of P450-containing monooxygenase systems. *Protein Engineering* 8: 737-747.
- de Morais SMF., Wilkinson GR., Blaisdell J., Nakamura K., Meyer UA. and Goldstein JA. 1994b. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. *Mol Pharmacol* 46: 594-598.
- de Morais SMF., Wilkinson GR., Blaisdell J., Nakamura K., Meyer UA. and Goldstein JA. 1994a. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. *J Biol Chem* 269: 15419-15422.
- de Morais SMF., Goldstein JA., Xie H-G., Huang S-L., Lu Y-Q., Xia H., Xiao Z-S., Ile N. and Zhou H-H. 1995. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. *Clin Pharm Ther* 58: 404-412.
- Desta Z., Zhao X., Flockhart DA., and Shin JG. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. *Clin Pharmacokinet* 41: 913-958.
- Edstein MD., Yeo AE. and Kyle DE. 1996. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. *Trans R Soc Trop Med Hyg* 90: 418-21.
- Feng HJ., Huang SL., Wang W., Zhou HH. 1998. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene

dose. *Br J Clin Pharmacol* 45:27-9.

- Ferguson RJ., de Morais SMF., Benhamou S., Bouchardy C., Blaisdell J., Ibeanu G., Wilkinson GR., Sarich TC., Wright JM., Dayer P. and Goldstein JA. 1998. A novel defect in human *CYP2C19*: Mutation of the initiation codon is responsible for poor metabolism of *S*-mephenytoin. *J Pharmacol Exp Ther* 284: 356-361.
- Flockhart DA., Clauw DJ., Sale EB., Hewett L. and Woosley RL. 1994. Pharmacogenetic characteristics of eosinophilia- myalgia syndrom. *Clin Pharm Ther* 56: 398-405.
- Furuta T., Ohashi K., Kamata T., Takashima M., Kosuge K., Kawasaki T., Hanai H., Kubota T., Ishizaki T., Kaneko E. 1998. Effect of genetic differences in omeprazole metabolism on cure rates for *Helicobacter pylori* infection and peptic ulcer. *Ann Intern Med* 129:1027-1030.
- Furuta T., Ohashi K., Kosuge K., Zhao XJ., Takashima M., Kimura M., Nishimoto M., Hanai H., Kaneko E., Ishizaki T. 1999. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. *Clin Pharmacol Ther* 65: 552-61.
- Furuta T., Shirai N., Takashima M., Xiao F., Hanai H. and Sugimura H. 2001. Effect of genotypic differences in CYP2C19 on cure rates for *Helicobacter pylori* infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. *Clin Pharmacol Ther* 69: 158-68.
- Furuta T., Shirai N., Takashima M., Watanabe F., Honda S., Takeuchi K., Iida T., Sato Y., Kajimura M., Futami H., Takkayanaki S., Yamada M., Ohashi K., Ishizaki T. and Hanai H. 2001. Effect of Cytochrome P450 2C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. *Clin Pharmacol Ther* 72: 453-460.

- Goldstein JA. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. *Br J Clin Pharmacol* 52: 349-355.
- Goldstein JA and de Morais SM. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics* 4:285-99.
- Goldstein JA. and Blaisdell J. 1996. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism in *Methods in Enzymology* 272; 210-217, *Academic Press San Diego CA* 272:210-217.
- Goldstein JA., Faletto MB., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy JL., Lasker JM. and Ghanayem BI. 1994. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. *Biochemistry* 33: 1743-1752.
- Goldstein JA., Ishizaki T., Chiba K., de Morais SMF., Bell D., Krahn PM. and Price Evans DA. 1997. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. *Pharmacogenetics* 7: 59-64.
- Gotoh O. 1992. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. *J Biol Chem* 267: 83-90.
- Glue P. and Banfield C. 1996. Psychiatry, psychopharmacology and P450s. *Hum Psychopharmacol* 11:97-114.
- Guengerich P. 2000. Common and uncommon Cytochrome P450 reactions related to metabolism and chemical toxicology. *Chemical Research in Toxicology* 14: 612-640.

- Hahn GJ. and Meeker WQ. 1997. Statistical Intervals: *A Guide for Practitioners*. 104-105.
- Halpert J.R. 1995. Structure basis of selective cytochrome P450 inhibition. *Ann Rev Pharmacol Toxicol* 35:29-53.
- He N., Yan FX., Huang SL., Wang W., Xiao ZS., Liu ZQ., Zhou HH. 2002. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. *Eur J Clin Pharmacol* 58: 15-8.
- Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. 1998. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. *Clin Pharmacol Ther* 64: 391-401.
- Ibeanu GC., Ghanayem BI., Linko P., Leiping L., Pedersen LG. and Goldstein JA. 1996 Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. *J Biol Chem* 271: 12496-12501.
- Ibeanu GC., Blaisdell J., Ghanayem BI., Beyeler C., Benhamou S., Bouchardy C., Wilkinson GR., Dayer P., Daly AK. and Goldstein JA. 1998. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. *Pharmacogenetics* 8: 129-135.
- Ibeanu GC., Blaisdell J., Ferguson RJ., Ghanayem BI., Brosen K., Benhamou S., Bouchardy C., Wilkinson GR., Dayer P., Goldstein JA. 1999. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. *Pharmacol Exp Ther* 290:635-40.

- Inaba T., Jurima M., Nakano M. and Kalow W. 1984. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. *Clin Pharmacol Ther.* 36:670-6.
- Jacqz E., Dulac H. and Mathieu H. 1998. Phenotyping polymorphic drug metabolism in the French Caucasian population. *Eur J Clin Pharmacol* 35:167-71.
- Jurima M., Inaba T., Kadar D. and Kalow W. 1985. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. *Br J Clin Pharmacol* 19:483-7.
- Jan van der Weide and Linda S W Steijns. 1999. Cytochromes P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. *Ann Clin Biochem* 36:722-729.
- John Wiley Sons, Inc Hasemann CA., Kurumbail RG., Boddupalli SS., Peterson JA. and Deisenhofer J. 1995. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. *Structure* 2: 41-62.
- Kaisary A., Smith P., Jacqz E., McAllister CB., Wilkinson GR. and Ray WA. 1987. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and S-mephenytoin as risk factor. *Cancer Res* 47: 5488-93.
- Kalow W. 1986. The genetic defect of mephenytoin hydroxylation. *Xenobiotica* 16:379-89.
- Keneko A., Keneko O., Taleo G., Bjorkman A. and Kobayakava T. 1997. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu (letter). *Lancet* 349:921-922.

- Kimura M., Ieiri I., Mamiya K., Urae A. and Higuchi S. 1998. Genetic polymorphism of the cytochrome P450s, CYP2C19 and CYP2C9 in Japanese population. *Ther Drug Monit* 20:243-7.
- Kubota T, Chiba K, Ishizaki T. 1996. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. *Clin Pharmacol Ther.* 60: 661-6.
- Küpfer A. and Preisig R. 1984. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. *Eur J Clin Pharmacol* 26: 753-759.
- Küpfer A. and Branch RA. 1985. Stereo selective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. *Clin Pharmacol Ther* 38: 414-418.
- Langerstrom PO. and Persson BA. 1984. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. *J Chromatogr* 309: 347-56.
- Lamba JK., Dhiman RK. and Kohli KK. 1998. Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects. *Clin Pharmacol Ther.* 63(4):422-7.
- Levy RH. 1995. Cytochrome P450 isozymes and antiepileptic drug interactions. *Epilepsia* 36: 8-13.
- Lillibridge JH., Lee CA. and Pithavala YK., 1998. The role of CYP2C19 in the formation of Nelfinavir hydroxy-t-butylamide in vitro/in vivo correlation *ISSX Proceedings* 13: 119-25.
- Lin J.H. and Lu A.Y.H. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. *Clin Pharmacokinet* 35: 361-390.

- Linder MW., Prough RA. and Valdes R. 1997. Pharmacogenetic: a laboratory tool for optimizing therapeutic efficiency. *Clin Chem* 1997 43: 254-66.
- Mamiya K., Hadama A., Yukawa E., Ieiri I., Otsubo K., Ninomiya H., Tashiro N., and Higuchi S. 2000. CYP2C19 polymorphism effect on phenobarbitone pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. *Eur J Clin Pharmacol* 55: 821-5.
- Marandi T., Dahl ML., Rago L., Kiivet R., Sjoqvist F. 1997. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. *Eur J Clin Pharmacol* 53:257-60.
- Marinac JS., Balian JD., Foxworth JW., Willsie SK., Daus JC., Owen R., Flockhart DA. 1996. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. *Clin Pharmacol Ther* 60: 138-44.
- Masimirembwa C., Bertilsson L., Johansson I., Hasler JA., Ingelman-Sundberg M. 1995. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450C19) in a Shona population of Zimbabwe. *Clin Pharmacol Ther* 57: 656-61.
- May DG. 1994. Genetic differences in drug disposition. *Clin Pharmacol Ther* 34: 881-97.
- Meier UT., Dayer P., Male PJ., Kronbach T. and Meyer UA. 1985. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. *Clin Pharmacol Ther* 38:488-94.
- Meyer J.M. and Rodvold K.A. 1996. Drug biotransformation by the cytochrome P-450 enzyme system. *Infect Med* 13(6):452,459,463-464,523.

- Morinobu S., Tanaka T., Kawakatsu S., Totsuka S., Koyama E., Chiba K., Ishizaki T., Kubota T. 1997. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. *Psychiatry Clin Neurosci.* 51:253-7.
- Murray M. 1992. P450 enzymes: inhibition mechanisms, genetic regulation and effect of liver disease. *Clin Pharmacokinetic* 23:132-46.
- Nakamura K. 1985. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. *Clin Pharmacol Ther.* 38: 402-408
- Nelson DR., Koymans LL., Kamataki T., StegemanJJ., Feyereisen R. and Waxman DJ. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetic* 6:1-42.
- Nielsen KK., Brøsen K., Hansen J. and Gram LF. 1994. Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. *Clin Pharmacol Ther* 55: 518-527.
- Omura T. and Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. *J Biol Chem* 239: 2370-2378.
- Olkola K.T., Backman J.T. and Neuvonen P.J. 1994. Midazolam should be avoided in patients receiving the systemic anmycotics ketoconazole or itraconazole. *Clin Pharmacol. Ther* 55: 481-485.
- Qin X.P., Xie H.G., Wang W. 1999. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. *Clin. Pharmacol. Ther* 66: 642-646.

- Raucy JL., Lasker JM., Lieber CS., and Black M. 1989. Acetaminophen activation by human liver cytochrome P450IIE1 and P4501A2. *Arch Biochem Biophys* 27: 270-83.
- Reviriego J., Bertilsson L., Carrillo JA., Llerena A., Valdivielso MJ. Benitez J. 1993. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. *Eur J Clin Pharmacol* 44:593-5.
- Richardson TH., Jung F., Griffin KJ., Wester M., Raucy JL., Kemper B., Bornheim LM., Hassett C., Omiecinski CJ. and Johnson EF. 1995. A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in *Escherichia coli*. *Arch Biochem Biophys* 323:87-96.
- Romkes M., Faletto MB., Blaisdell J., Raucy JL. and Goldstein JA. 1991. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. *Biochemistry* 30: 3247-3255.
- Sanz EJ., Villen T., Alm C. and Bertilsson L. 1989. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. *Clin Pharmacol Ther* 45: 495-499.
- Sarker M. and Duchin. 1988. Theophylline N-demethylation as probes for P4501A1 and P4501A2. *Drug Metab Dispo* 22: 125-34.
- Sarich T., Kalhorn T., Magee S., Al-Sayegh F., Adams S., Slattery J., Goldstein J., Nelson S. and Wright J. 1997. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. *Clin Pharm Ther* 62: 21-28.
- Setiabudy R., Chiba K., Kusuka M. and Ishizaki T. 1992. Caution in the use of 100 mg of

- Racemic S-mephenytoin for phenotyping Southeastern Oriental subjects. *Br J Clin Pharmacol* 33: 665-6.
- Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich FP. 1994. Interindividual variation in human liver cytochrome P450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 270:414-23.
- Shin JG., Park JY., Kim MJ., Shon JH., Yoon YR., Cha J., Lee SS., Oh SW., Kim SW., Flockhart DA. 2002. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. *Drug Metab Dispos.* 30: 1102-7.
- Shirai N., Furuta T., Xiao F., Kajimura Y. and Hanai H. 2001. Effects of CYP2C19 genotypic differences in the metabolism omeprazole and rabeprazole on intragastric pH. *Aliment Pharmacol Ther* 15: 1929-37.
- Sohn DR., Kwon JT., Kim HK. And Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. *Clin Pharmacol Ther* 61: 574-82.
- Shu Y. and Zhou H.H. 2000. Individual and ethnic differences in CYP2C19 activity in Chinese populations. *Acta. Pharmacol. Sin.* 21 193-199.
- Shu Y., Wang L.S., Xu Z.H. 2000. 5-Hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. *J. Pharmacol. Exp. Ther.* 295: 844-851
- Sindrup SH., Brøsen K., Hansen MGJ., Aaes-Jorgensen T., Overo KF. and Gram LF.

1993. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. *Ther Drug Monit* 13: 11-17.

Skjelbo E., Brøsen K., Hallas J. and Gram LF. 1991. The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. *Clin Pharmacol Ther* 49: 18-23.

Smith DA., Jone BC. and Chandler MH. 1991. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. *Biochem Pharmacol* 44: 2089-98.

Sohn DR., Kwon JT., and Kim hk. 1997. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. *Clin Pharmacol Ther* 47:410-418.

Svensen USH., Asthan M., Hai TN., Bertilson L., Huong DX. and Huong NV. 1998. Artemisinin induces omeprazole metabolism in human being. *Clin Pharmacol Ther* 64:160-7.

Sviri S., Shpizen S., Leitersdorf E., Levy M., Caraco Y. 1999. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. *Clin Pharmacol Ther* 65:275-82.

Tamminga WJ., Wemer J., Oosterhuis B., de Zeeuw RA., de Leij LF., Jonkman JH. 2001. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. *Eur J Clin Pharmacol*. 57:717-22.

Tassaneeyakul W., Tawalee A., Tassaneeyakul W., Kukongviriyapan V., Blaisdell J., Goldstein JA, Gaysornsiri D. 2002. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. *Pharmacogenetics* 12: 221-225.

- Tassaneeyakul W., Tawalee A. and Tassaneeyakul W., 2000. Review Genetic Polymorphism of Cytochrome P450C19. *Thai Journal of pharmacology* 22:121-136.
- Tybring G. and Bertilsson L. 1992. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. *Pharmacogenetics* 2:241-3.
- Villika K., Kivisto KT., Backman JT., Olkkla KT., Neuvoman PJ. 1997. Trizolam is ineffective in patients taking rifampicin. *Clin Pharmacol Ther* 61: 8-14.
- Villika K., Kivisto KT. and Neuvoman PJ. 1999. The ineffective of rifampicin on the pharmacokinetics of oral and intravenous ondansetron. *Clin Pharmacol Ther* 65:337-81.
- Vogel F. 1959. Moderne problem der humangenetik. Ergebnisse Inneren. *Medizin und kinderheilkunde* 12, 52-125.
- Wan J., Xia H., He N., Lu YQ., Zhou HH. 1996. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. *Br J Clin Pharmacol* 42:471-4.
- Ward SA., Walle T., Walle UK., Wilkinson GR. and Branch RA. 1989. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. *Clin Pharmacol Ther* 45: 72-79.
- Ward SA., Helsby NA., Skejlbo E., Brøsen K., Gram LF. and Breckenridge AM. 1991. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. *Br J Clin Pharmacol* 31: 689-692.

- Wedlund P.J., Sweetman B.J., McAllister C.B., Branch R.A. and Wilkinson G.R. 1984. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. *J Chromatogr B Biomed Appl* 307: 121-127.
- Wedlund P.J., Aslanian W.S., E. Jacqz, C.B. McAllister, R.A. Branch and G.R. Wilkinson 1985. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. *J. Pharmacol. Exp. Ther.* 234 : 662–669.
- Wedlund P.J., Sweetman B.J., Wilkinson G.R. and Branch R.A. 1987. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. *Drug Metab Dispos* 15: 277-279.
- Wilkinson G.R., Guengerich F.P. and Branch R.A. 1989. Genetic polymorphism of S-mephenytoin hydroxylation. *Pharmacol Ther* 43: 53-76.
- Wrighton S.A., Stevens J.C., Becker G.W. and Vanden Branden M. 1993. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. *Arch Biochem Biophys* 306: 240-245.
- Xie H.G., Huang S.L. and Zhou H.H. 1995. High performance liquid chromatographic determination of urinary 4'-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. *J Chromatogr B Biomed* 668:125–131.
- Xiao Z.S., Goldstein J.A., Xie H-G., Blaisdell J., Wang W., Jiang C-H., Yan F-X., He N., Huang S-L., Xu Z-H. and Zhou H-H. 1997. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. *J Pharmacol Exper Ther* 281: 604-609.

Yamada S., Onda M., Kato S., Matsuda N., Matsuhisa T., Yamada N., Miki M. and Matsukura N. 2001. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. *J Gastroenterol* ;36:669-72.

Zhang Y., Blouin RA., McNamara PJ., Steinmetz J. and Wedlund PJ. 1992. Limitation to the use of urinary *S/R* mephenytoin ratio in pharmacogenetic studies. *Br J Clin Pharmacol* 31: 350-352.

Zhou H.H, Feng, S.L., Huang and W. Wang. 1990. The induction effect of rifampicin on activity of mephenytoin 4-hydroxylase related to *CYP2C19*2* mutation of CYP2C19 and gene dose. *Br. J. Clin. Pharmacol* 45: 27-29.

Zhou H.H., Anthony L.B., Wood A.J.J. and G.R. Wilkinson.1998. Induction of polymorphic 4-hydroxylation of *S*-mephenytoin by rifampicin. *Br. J. Clin. Pharmacol.* 30:27-34.

Zhou H.H. 2001. CYP2C19 genotype determines enzyme activity and inducibility of *S*-mephenytoin hydroxylase*1. *Pharmacogenetics* 313:203-208.

Website <http://www.imm.ki.se/CYPalleles/cyp2c19.htm>.